<DOC>
	<DOCNO>NCT02722798</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety KRN23 48-week every 4 week repeat subcutaneous administration Japanese Korean patient Tumor-Induced Osteomalacia Epidermal Nevus Syndrome multicenter , open-label , intraindividual dose adjustment study</brief_summary>
	<brief_title>A Study KRN23 Subjects With Tumor-Induced Osteomalacia Epidermal Nevus Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nevus</mesh_term>
	<mesh_term>Osteomalacia</mesh_term>
	<mesh_term>Neoplasms , Connective Tissue</mesh_term>
	<mesh_term>Nevus , Sebaceous Jadassohn</mesh_term>
	<criteria>1 . Aged ≥ 18 year 2 . Diagnosis TumorInduced Osteomalacia ( TIO ) Epidermal Nevus Syndrome ( ENS ) amenable receive surgical excision offend tumor/lesion 3 . Serum phosphorus level &lt; 2.5 mg/dL 4 . Serum FGF23 level ≥ 100 pg/mL 5 . Ratio renal tubular maximum phosphate reabsorption rate glomerular filtration rate &lt; 2.5 mg/dL 6 . Estimated glomerular filtration rate ( eGFR ) screen ≥ 60 mL/min/1.73 m2 , eGFR ≥ 30 &lt; 60 mL/min/1.73 m2 evidence renal failure relate nephrocalcinosis 7 . Corrected serum calcium level &lt; 10.8 mg/dL 8 . For female subject childbearing potential ; negative urine pregnancy test willingness undergo additional pregnancy test study 9 . Willingness use acceptable method contraception participate study 10 . Willingness provide access prior medical record determine eligibility include data imaging test , blood chemistry , diagnosis , medication , surgical history 11 . Willingness ability cooperatively complete study procedure , adhere visit schedule follow investigator 's instruction , consider investigator subinvestigator 1 . Use follow drug within 14 day prior screen : pharmacologic vitamin D metabolites analog , drug treat TIO/ENS include oral phosphate , aluminum hydroxide antacid , acetazolamide , thiazide diuretic 2 . Medication suppress parathyroid hormone ( PTH ) within 60 day prior screen 3 . Blood blood product transfusion within 60 day prior screen 4 . Chemotherapy TIO malignant tumor within 4 month prior screen 5 . History positive human immunodeficiency virus antibody , hepatitis B antigen and/or hepatitis C virus antibody 6 . Predisposition infection , history recurrent infection know immunodeficiency 7 . Pregnant breastfeed screen intention become pregnant study ; male subject , partner 's intention become pregnant study 8 . Use investigational product device within 4 month prior screen , plan receive investigational product complete assessment study 9 . Use therapeutic monoclonal antibody include KRN23 within 90 day prior screen 10 . History allergic anaphylactic reaction KRN23 , KRN23 ingredient , monoclonal antibody 11 . Anyone otherwise consider unsuitable participation study investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>